Alume Biosciences

Alume Biosciences is pioneering a precision surgery platform with its proprietary nerve-targeted fluorescent imaging agent, ALM-488. Founded in 2017 based on research from a Nobel Laureate, the company's technology aims to reduce iatrogenic nerve damage in complex surgeries, potentially improving functional outcomes for patients. With its lead program in Phase 3 trials and a planned NDA submission in 2026, Alume is positioned to address a significant unmet need in surgical oncology and beyond. The company has garnered support from key surgical thought leaders who recognize the transformative potential of intraoperative nerve visualization.

Proprietary nerve-targeting fluorescent peptide conjugate (bevonescein/ALM-488) for real-time intraoperative visualization of nerves under near-infrared light.

The field of fluorescence-guided surgery is growing, but Alume appears to be the first with a specific nerve-targeting agent in late-stage trials. Competition includes general contrast agents (e.g., indocyanine green) and advanced neuromonitoring systems, but none offer direct, real-time visual highlighting of nerve structures.